Has Mounjaro Been Approved for Weight Loss — and What That Means for You

Step 1: The MHRA reviewed the full trial programme and granted the licence

Before any medicine reaches UK patients, the MHRA examines data from clinical trials covering safety, efficacy and quality. For tirzepatide, that review centred on the SURMOUNT programme, a series of trials involving thousands of adults living with obesity or overweight. SURMOUNT-1, published in the New England Journal of Medicine, reported average body-weight reductions of around 20–21% at the highest dose over 72 weeks among adults without diabetes. Those results, alongside the wider safety data, supported the MHRA's decision to grant Mounjaro a UK licence for weight management in 2023.

The licence is specific about what treatment is for: weight management alongside lifestyle changes, not as a standalone quick fix. If you want a clear answer to whether Mounjaro is approved for weight loss and what conditions that approval actually covers, that question is worth looking at before assuming you qualify. That distinction matters when you're trying to work out whether you qualify.

If you want to trace the full regulatory history, the Mounjaro approval timeline page goes into more depth on the milestones.

Step 2: NICE assessed cost-effectiveness and set NHS eligibility thresholds

Regulatory approval from the MHRA and NHS availability are two separate questions. After the MHRA licence, NICE conducted its own appraisal to decide whether tirzepatide represents value for the NHS. In December 2024, NICE published TA1026, recommending tirzepatide for NHS use, but with specific eligibility criteria that are narrower than the licensed indication.

Under TA1026, NHS patients qualify if they have a BMI of 35 or above alongside at least one weight-related comorbidity. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance, 2.5 kg/m² lower for those of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean heritage. NHS rollout is phased, so not everyone who meets the criteria can access treatment immediately. From around June 2026, people with a BMI between 35 and 39.9 alongside four or more qualifying conditions became eligible under Cohort 2.

Private prescribing follows the licensed criteria rather than the NHS thresholds, which is why the two routes can look quite different in practice.

Step 3: Understanding what licensed actually means for you personally

A licence sets the legal framework within which a prescriber can act, it does not automatically mean everyone who reads the eligibility criteria will be approved. Prescribers weigh your full medical history, current medications, any contraindications and the likely balance of benefit and risk. Conditions such as a personal or family history of medullary thyroid carcinoma, or certain gastrointestinal conditions, require careful discussion before treatment is appropriate.

Common side effects are led by the digestive system, nausea, constipation, loose stools and indigestion are the most frequently reported, particularly in the weeks after starting or after a dose change. Most people find these settle. The evidence behind Mounjaro page covers what the trial populations experienced in more detail, and the NHS patient information for tirzepatide is worth reading before your consultation.

One practical note: Mounjaro is supplied as a pre-filled KwikPen kept in the fridge (most people keep it in the fridge door alongside everyday items) and each pen contains four weekly doses. Storage requirements and the exact room-temperature window are set out in the Patient Information Leaflet; always follow that rather than general guidance.

Step 4: How private access through a regulated pharmacy works

If you do not yet meet the NHS thresholds, or prefer not to wait, a private prescription through a GPhC-registered pharmacy is the legal alternative. At nume, every consultation is read by a GPhC-registered Independent Prescriber (a real clinician, on the same day) who decides whether treatment is appropriate for you. There is no algorithm making that call.

The process involves identity and weight verification before anything is dispensed. If approved, treatment is dispatched the same day for orders placed before noon Monday to Friday, arriving by tracked DPD the next working day in plain packaging. For a fuller picture of what private treatment costs and what is included in the price, the Mounjaro cost page sets out the honest answer without hidden fees.

Mounjaro is also being studied for conditions beyond weight management. If you're curious about the sleep apnoea research, there is a separate page on when Mounjaro may be approved for sleep apnoea in the UK. When you're ready to check whether you're a candidate for treatment, starting a free consultation is the straightforward next step.